ACIU

AC Immune SA

2.05

Nov 02 • 2:22 PM ET -0.17 (-7.66%)

Healthcare Biotechnology Switzerland Micro NASD

Peers: PRTA ABOS ALEC VYGR AVXL DNLI BIIB INMB ANVS LLY

| Held by: IBB DFAS DFMC DXUV DFAC IBBQ DCOR BIB DFSU

Index	-
Market Cap	208.64M
Enterprise Value	120.31M
Income	-54.32M
Sales	22.15M
Book/sh	0.48
Cash/sh	0.92
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	122
IPO	Sep 23, 2016

P/E	-
Forward P/E	8.39
PEG	-
P/S	9.42
P/B	4.28
P/C	2.23
P/FCF	-
EV/EBITDA	-
EV/Sales	5.43
Quick Ratio	0.93
Current Ratio	0.93
Debt/Eq	0.12
LT Debt/Eq	0.09
Option/Short	Yes / Yes

EPS (ttm)	-0.56
EPS next Y	0.24
EPS next Q	-0.18
EPS this Y	39.81%
EPS next Y	147.77%
EPS next 5Y	-
EPS past 3/5Y	1.71% 1.71%
Sales past 3/5Y	1.45% -23.52%
EPS Y/Y TTM	4.48%
Sales Y/Y TTM	-33.68%
EPS Q/Q	110.21%
Sales Q/Q	1110.62%
Earnings	Aug 05 BMO
EPS/Sales Surpr.	121.61% 98.88%

Insider Own	38.53%
Insider Trans	-0.03%
Inst Own	24.21%
Inst Trans	-1.63%
ROA	-25.54%
ROE	-79.01%
ROIC	-113.99%
Gross Margin	-
Oper. Margin	-249.40%
Profit Margin	-245.27%
SMA20	-14.79%
SMA50	-21.04%
SMA200	-24.58%
Trades

Shs Outstand	91.10M
Shs Float	62.56M
Short Float	5.22%
Short Ratio	16.36
Short Interest	3.26M
52W High	3.90 -47.44%
52W Low	2.03 0.99%
Volatility	8.61% 5.09%
ATR (14)	0.15
RSI (14)	30.34
Beta	1.64
Rel Volume	2.65
Avg Volume	199.55K
Volume	408,795

Perf Week	-11.26%
Perf Month	-24.77%
Perf Quarter	-9.69%
Perf Half Y	-32.79%
Perf YTD	-34.71%
Perf Year	-39.35%
Perf 3Y	-27.56%
Perf 5Y	-71.05%
Perf 10Y	-82.99%
Recom	1.00
Target Price	8.63
Prev Close	2.22
Price	2.05
Change %	-7.66%

Consensus

Strong Buy

Avg. Price Target

$8.63

Implied Upside

+321.0%

Analysts6incl. previous ratings

Rating Distribution4 Buy · 2 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
May 31, 2024	Initiated	BBTIG Research	Buy	$8	+290.2%
Feb 01, 2019	Downgrade	UUBS	Buy → Neutral
Jan 04, 2019	Initiated	UUBS	Buy
Apr 05, 2018	Initiated	HH.C. Wainwright	Buy	$18	+778.0%
Mar 23, 2018	Downgrade	CCredit Suisse	Outperform → Neutral
Oct 18, 2016	Initiated	LLeerink Partners	Outperform
Oct 18, 2016	Initiated	JJefferies	Buy	$25	+1,119.5%
Oct 18, 2016	Initiated	CCredit Suisse	Outperform	$18	+778.0%

Sep-23-26 07:00AM	AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104 (GlobeNewswire)
Aug-20-26 09:35AM	AC Immune shares rise after encouraging early Phase 1 data for ACI-19764 (InvestorsHub)
07:00AM	AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764 (GlobeNewswire)
Aug-11-26 12:18PM	ACIU Stock Heads For Best Day In Over 10 Months On FDA Fast Track Nod For Parkinsons Disease Therapy Retail Sees Breakout Soon (Stocktwits) +11.40%
07:00AM	AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson's Disease (PD) (GlobeNewswire)
08:00AM	Loading…
Aug-05-26 08:00AM	AC Immune: Q2 Earnings Snapshot (Associated Press)
07:00AM	AC Immune First Half 2026 Financial and Corporate Update (GlobeNewswire)
Jul-07-26 07:00AM	AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC 2026 (GlobeNewswire)
Jun-30-26 07:00AM	AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer's Disease (GlobeNewswire) -10.53%
Jun-11-26 07:00AM	AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson's Disease (GlobeNewswire) +6.60%
May-22-26 07:00AM	AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS (GlobeNewswire)
May-13-26 06:27AM	Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B (BioPharma Dive)
May-12-26 07:00AM	AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM (GlobeNewswire)
Apr-30-26 07:13AM	AC Immune: Q1 Earnings Snapshot (Associated Press)
07:05AM	AC Immune First Quarter 2026 Financial and Corporate Updates (GlobeNewswire)
07:00AM	Loading…
07:00AM	AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease (GlobeNewswire)
Apr-09-26 08:01PM	Is AC Immune (ACIU) Stock Outpacing Its Medical Peers This Year? (Quartz) +5.92%
Apr-07-26 07:00AM	AC Immune Announces Amendment to Morphomer Tau License and Collaboration Agreement with Lilly (GlobeNewswire) +15.19%
Mar-19-26 07:00AM	AC Immune Presents First In vivo Images of Brain TDP-43 Pathology from Phase 1 Trial of PET tracer ACI-19626, at AD/PDTM 2026 (GlobeNewswire)
Mar-13-26 07:11AM	AC Immune: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update (GlobeNewswire)
Mar-05-26 07:00AM	AC Immune Announces Upcoming Industry Symposium on Parkinson's Disease and Presentation at AD/PD 2026 (GlobeNewswire)
Feb-24-26 07:00AM	AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor (GlobeNewswire) +7.51%
Feb-20-26 05:23AM	Madrigal sees a stock sell-off; ex-Novartis exec heads to Daiichi (BioPharma Dive)
Dec-26-25 10:00AM	Startup Lifordi Seeks to Deliver Potent Medication for Autoimmune Diseases (The Wall Street Journal)
Dec-11-25 08:36AM	AC Immune posts positive data for Parkinsons immunotherapy (BioPharma Dive) +15.41%
07:00AM	AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson's Disease (GlobeNewswire)
Nov-11-25 07:00AM	AC Immune to Present at the Jefferies 2025 London Healthcare Conference (GlobeNewswire)
Nov-04-25 08:55AM	AC Immune (ACIU) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:48AM	AC Immune: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Loading…
07:00AM	AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update (GlobeNewswire)
Oct-29-25 10:00AM	Alector (ALEC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks) +9.09%
Oct-28-25 10:00AM	Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline (Zacks)
07:00AM	AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board (GlobeNewswire)
Oct-24-25 08:50AM	First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune's ACI-19626 in Precision Medicine (GlobeNewswire) +15.66%
Oct-09-25 09:23AM	Intellia Therapeutics (NTLA) Soars 19.7%: Is Further Upside Left in the Stock? (Zacks)
Sep-25-25 07:00AM	Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine (GlobeNewswire) +6.59%
Sep-04-25 03:45AM	AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway (GlobeNewswire)
Aug-06-25 06:56AM	New Strong Sell Stocks for August 6th (Zacks) -11.43%
Aug-05-25 08:15AM	AC Immune (ACIU) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +11.62%
07:21AM	AC Immune: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update (GlobeNewswire)
Jul-30-25 10:00AM	Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy? (Zacks) -7.23%
Jul-29-25 10:00AM	AC Immune (ACIU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release (Zacks)
Apr-30-25 08:15AM	AC Immune (ACIU) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:15AM	AC Immune: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update (GlobeNewswire)
Apr-03-25 09:46AM	AC Immune reports interim outcomes from trial of Parkinsons therapy (Clinical Trials Arena) -5.85%
Apr-02-25 06:00AM	AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease (GlobeNewswire)
Mar-25-25 07:00AM	AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD 2025 (GlobeNewswire) -6.60%
Mar-24-25 03:00PM	ACIU Stock Crashes 18.3% in a Month: Buy, Sell or Hold? (Zacks)
Mar-13-25 07:00AM	AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Mar-05-25 12:00PM	AC Immune (ACIU) Upgraded to Strong Buy: Here's What You Should Know (Zacks) +6.38%
Mar-04-25 07:00AM	AC Immune to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-13-25 09:35AM	Down -9.7% in 4 Weeks, Here's Why You Should You Buy the Dip in AC Immune (ACIU) (Zacks) +10.74%
Dec-11-24 07:26AM	AC Immune announces interim safety, tolerability data from ABATE Phase 1b/2 (TipRanks)
Dec-10-24 07:00AM	AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome (GlobeNewswire)
Nov-15-24 12:33PM	AC Immunes stock jumps after Parkinsons therapy shows signs of benefit (Pharmaceutical Technology) -10.14%
07:30AM	AC Immune reports interim results from Phase 2 trial of ACI-7104.056 (TipRanks)
Nov-14-24 07:00AM	AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease (GlobeNewswire) +13.42%
Nov-13-24 07:00AM	AC Immune to Present at the Jefferies 2024 London Healthcare Conference (GlobeNewswire)
Nov-05-24 07:30AM	AC Immune: Q3 Earnings Snapshot (Associated Press Finance) +10.20%
07:00AM	AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Oct-23-24 09:12AM	What To Expect From AC Immune SA (ACIU) Q3 2024 Earnings (GuruFocus.com)
Sep-17-24 07:00AM	AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer's Disease (GlobeNewswire) +5.81%
Aug-29-24 07:13AM	FDA grants fast track designation to Life Molecular Imagings tau PET diagnostic (Medical Device Network)
Aug-28-24 09:00AM	AC Immune's PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions (GlobeNewswire)
Aug-06-24 09:25AM	AC Immune (ACIU) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
08:23AM	AC Immune: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Jul-31-24 08:30AM	AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024 (GlobeNewswire)
Jul-25-24 12:53PM	AC Immune wins FDA fast track for Alzheimers vaccine (Pharmaceutical Technology) +10.76%
07:00AM	AC Immune's ACI-35.030 (now "JNJ-2056") Granted FDA Fast Track Designation for Alzheimer's Disease (GlobeNewswire)
Jul-16-24 07:00AM	AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024 (GlobeNewswire) +5.15%
May-28-24 07:00AM	AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024 (GlobeNewswire) +9.32%
May-13-24 03:58PM	Sector Update: Health Care Stocks Mixed Late Afternoon (MT Newswires) +42.86%
03:37PM	Sector Update: Health Care (MT Newswires)
02:53PM	ACIU Stock Earnings: AC Immune Misses EPS for Q1 2024 (InvestorPlace)
02:41PM	Top Midday Gainers (MT Newswires)
11:22AM	Takeda shells out $100m to license AC Immunes Phase II Alzheimers therapy (Pharmaceutical Technology)
08:13AM	Why Is AC Immune (ACIU) Stock Up 45% Today? (InvestorPlace)
08:02AM	Takeda nabs option to license Alzheimers immunotherapies from AC Immune (BioPharma Dive)
08:00AM	Top Premarket Gainers (MT Newswires)
07:26AM	Takeda Pharmaceutical, AC Immune Agree to Option and Licence Agreement, Including on Alzheimer's Treatment Candidate (MT Newswires)
07:23AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
06:12AM	AC Immune: Q1 Earnings Snapshot (Associated Press Finance)
06:05AM	AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
06:00AM	AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimers Disease (Business Wire)
05:52AM	Takeda pays AC Immune $100M upfront for Alzheimer's drug as phase 2 readout nears (FierceBiotech.com)
Mar-14-24 10:52PM	ACIU Stock Earnings: AC Immune Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) -10.00% +5.11%
07:00AM	AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update (GlobeNewswire)
Feb-22-24 07:00AM	AC Immune Announces Upcoming Presentations at AD/PD 2024 (GlobeNewswire)
Feb-21-24 11:16AM	5 Little-Known Penny Stocks With Massive Upside Potential (Insider Monkey)
Jan-30-24 09:35AM	Down -35.7% in 4 Weeks, Here's Why AC Immune (ACIU) Looks Ripe for a Turnaround (Zacks)
Jan-22-24 08:48AM	Roche's Genentech returns Alzheimer's assets to AC Immune, cutting 18-year tie to the biotech (FierceBiotech.com)
07:00AM	AC Immune to Regain Global Rights to Crenezumab and Semorinemab (GlobeNewswire)
Jan-18-24 12:00PM	AC Immune (ACIU) is a Great Momentum Stock: Should You Buy? (Zacks)
Jan-03-24 12:00PM	AC Immune (ACIU) Upgraded to Buy: Here's Why (Zacks)
08:10AM	AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases (GlobeNewswire)
Dec-15-23 07:56AM	AC Immune Announces Pricing of Underwritten Offering of Common Shares (GlobeNewswire) +5.66%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Pfeifer Andrea	Chief Executive Officer	May 15 '26	Sale	2.79	10,000	27,935	3,820,288	May 18 04:25 PM
ANDREA M.A PFEIFER	Director	May 15 '26	Proposed Sale	2.80	20,000	56,000		May 15 04:26 PM
ANDREA M.A PFEIFER	Officer	Apr 15 '26	Proposed Sale	3.19	10,000	31,900		Apr 15 04:52 PM
ANDREA M.A PFEIFER	Officer	Jan 15 '26	Proposed Sale	3.67	30,000	110,100		Jan 15 04:25 PM

AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eliseev on February 13, 2003 and is headquartered in Lausanne, Switzerland.

Chief Operating OfficerMr. Piergiorgio Donati

Senior VP of Investor Relations & Corporate CommunicationsDr. Gary Anthony Waanders Ph.D.

Senior VP & General CounselDr. Matthias Maurer Ph.D.

Senior Vice President of Regulatory Affairs & Quality AssuranceDr. Julien Rongere Ph.D.

Executive Vice President of Information Systems & Artificial IntelligenceMr. Mark Danton

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ACIU

AC Immune SA

Upgrade your Finviz experience